Reported Earnings • Jul 07
Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2026 results: US$12.64 loss per share (improved from US$40.62 loss in FY 2025). Net loss: US$5.02m (loss narrowed 17% from FY 2025). Revenue exceeded analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%. New Risk • Jun 20
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Shareholders have been substantially diluted in the past year (359% increase in shares outstanding). Revenue is less than US$1m (US$3.0k revenue). Market cap is less than US$10m (US$3.45m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$5.1m net loss next year). Ankündigung • May 26
Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes Virax Biolabs Group Limited reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV"). ViraxImmune™ has now been evaluated in more than 120 subjects in the Company's ongoing UK clinical study in Long COVID, ME/CFS and related post-acute infection syndromes. Virax is preparing for its next major development milestone: a larger clinical validation analysis involving previously collected samples from 300 additional participants, with analysis expected to begin in Fourth Quarter 2026 and results expected in First Quarter 2027. Findings support continued advancement toward Virax's intended U.S. market-entry strategy: an initial PAIS-focused U.S. Laboratory Developed Test ("LDT") route, with broader in vitro diagnostic ("IVD") development planned over time. If validated in larger studies, ViraxImmune™ could become one of the first objective immune-profiling approaches developed specifically for Long COVID, ME/CFS and related post-acute infection syndromes. ViraxImmune™ is in development and is not approved for diagnostic use in any jurisdiction. The VRX003 observations are preliminary and are intended to inform ongoing assay development and future clinical validation planning. New Risk • Apr 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m (US$3.0k revenue). Market cap is less than US$10m (US$1.11m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$5.1m net loss next year). Ankündigung • Mar 19
Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association Virax Biolabs Group Limited at its AGM held on March 11, 2026 shareholders approved the form of the fourth amended and restated memorandum and articles of association of the Company in the form attached as Exhibit 99.4 filed as part of the Form 6-K report filed on January 30, 2026 containing the Notice of Meeting and Proxy Statement in its entirety and in substitution for, and to the exclusion of, the existing memorandum and articles of association of the Company to reflect the revised authorized share capital, with effect from the effective date of the Share Consolidation. Reported Earnings • Dec 05
First half 2026 earnings released: US$0.49 loss per share (vs US$0.89 loss in 1H 2025) First half 2026 results: US$0.49 loss per share (improved from US$0.89 loss in 1H 2025). Net loss: US$2.34m (loss narrowed 15% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Ankündigung • Dec 04
Virax Biolabs Group Limited announced that it expects to receive $5 million in funding Virax Biolabs Group Limited announced that it has entered into a definitive agreement to issue 12,500,000 ordinary shares at an issue price of $0.40 for gross proceeds of $5,000,000 and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares for aggregate proceeds of $5,000,000 before deducting placement agent fees and other offering expenses on December 3, 2025. The preferred investment options have an exercise price of $0.40 per ordinary share and will be exercisable immediately upon issuance for a period of five years from the effective date of the initial registration statement. The private placement is expected to close on or about December 4, 2025, subject to the satisfaction of customary closing conditions. Ankündigung • Nov 05
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive Fda Feedback for Viraximmune™? Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes Virax Biolabs Group Limited announced that it has successfully completed patient recruitment for its United Kingdom-based, multi-centre clinical study evaluating the performance of the ViraxImmune™? assay in detecting T cell dysfunction in Post-Acute Infection Syndromes ("PAIS"), including Long COVID, post-treatment Lyme disease ("PTLD"), and Myalgic Encephalomyelitis /Chronic Fatigue Syndrome ("ME/CFS"). The study, conducted in collaboration with the UK's National Health Service ("NHS"), has achieved full enrolment ahead of schedule, reaching its target of 160 participants. It was randomised in a 3:1 ratio between symptomatic and non-symptomatic participants, with 40 patients recruited for each of the three symptomatic cohorts representing Long COVID, PTLD, and ME/CFS. In parallel, Virax announced that it received final minutes from its productive pre-submission meeting with the U.S. Food and Drug Administration ("FDA") on September 10, 2025, to discuss the proposed regulatory pathway for its ViraxImmune™? T cell assay. The meeting provided constructive feedback on the Company's continued development of the assay for use in patients with post-acute COVID-19 infection. Virax is incorporating the Agency's recommendations into its ongoing clinical and analytical development programs to support progress toward a future submission in the United States. The Company anticipates commencing its U.S.-based clinical study in 2026 in partnership with Emory University. Initial read-outs from this longitudinal study are expected in second quarter 2026. New Risk • Aug 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m (US$6.3k revenue). Market cap is less than US$10m (US$2.58m market cap). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.9m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Ankündigung • Jul 30
Virax Biolabs Group Limited Announces Board Changes Virax Biolabs Group Limited announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025. Dr. Miller succeeds Yair Erez, who is stepping down from the Board to focus on other professional endeavours. The Company thanks Mr. Erez for his valuable service and contributions. Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at GE Healthcare, bioMérieux, and Massachusetts General Hospital. He has worked extensively across both the United Kingdom and United States markets and has founded and led four MedTech companies, including Presymptom Health, a UK Ministry of Defence spinout, where he served as Chief Executive Officer. Under his leadership, Presymptom Health developed InfectiClear®, a novel diagnostic for infectious diseases. Dr. Miller has also served on the UK's NICE Technology Appraisal Committee and contributed to innovation programmes at NHS England and the Medicines and Healthcare products Regulatory Agency (MHRA). He holds a PhD in BioEngineering from the University of Strathclyde, an MBA from the University of Edinburgh, and a BSc in Physics & Electronics from the University of Glasgow. He has published extensively on diagnostic innovation. His commercial, technical, and regulatory expertise is expected to contribute meaningfully to Virax's business strategy as the Company works to expand its immune profiling platform into new markets. New Risk • Jul 03
New major risk - Revenue and earnings growth Earnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.2m free cash flow). Earnings have declined by 42% per year over the past 5 years. Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (US$6.3k revenue). Market cap is less than US$10m (US$3.69m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$5.9m net loss next year). Reported Earnings • Jul 03
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: US$1.63 loss per share (improved from US$3.36 loss in FY 2024). Net loss: US$6.06m (loss narrowed 10.0% from FY 2024). Revenue missed analyst estimates by 75%. Earnings per share (EPS) also missed analyst estimates by 9.5%. New Risk • Jun 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (US$85k revenue). Market cap is less than US$10m (US$4.25m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$5.8m net loss next year). Share price has been volatile over the past 3 months (12% average weekly change). Ankündigung • Mar 19
Virax Biolabs Group Limited Enrolls First Patients in Clinical Study Assessing T Cell Dysfunction in Post-Acute Infection Syndromes Virax Biolabs Group Limited announced that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179). Conducted in collaboration with the United Kingdom's National Health Service, investigators aim to assess the ViraxImmune™ FluoroSpot T cell assay performance in detecting T cell dysfunction in post-acute infection syndrome patients, including those with long COVID, post-treatment Lyme disease (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). As part of the regulatory approval pathway, up to 200 participants will be enrolled into the study, with initial data from this longitudinal assessment expected in Second Quarter 2026. Ankündigung • Mar 14
Virax Biolabs Group Limited Presents Data on T-Cell Dysfunction in Post-Acute Infection Syndromes at the 19th World Immune Regulation Meeting Virax Biolabs Group Limited announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland. PAISs are often associated with a dysfunction of the immune system, notably progressive T-Cell exhaustion. Chronic antigen stimulation following a chronic infection can cause upregulation of T-Cell exhaustion markers. Data demonstrated that repeated stimulation of peripheral blood mononuclear cells (PBMCs) with SARS-CoV-2 and CMV peptide pools increases the proportion of CD4+ and CD8+ T-Cells expressing exhaustion markers PD-1, LAG-3, TIGIT, TIM-3, and CD39 with each stimulation cycle. T-Cell exhaustion is well documented to correlate with reduced cytokine production, particularly of pro-inflammatory cytokines, resulting in impaired immune functionality. Additionally, preliminary data from the ViraxImmune™? PAIS assay showed significant changes in the levels of a number of cytokines investigated in patients with PAIS compared to healthy controls. Ankündigung • Dec 18
Virax Biolabs Initiates UK Clinical Study for ViraxImmune™ Platform to Detect T-Cell Dysfunction in Post-Acute Infectious Syndrome Patients Virax Biolabs Group Limited announced the initiation of a clinical study in the United Kingdom (NCT06731179) aimed at assessing the ViraxImmune™ platform's performance in detecting T-cell dysfunction in post-acute infectious syndrome patients, including those with long COVID, post-treatment Lyme disease (PTLD), and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The study will enroll up to 160 participants, with first patient dosed anticipated in early First Quarter 2025, followed by initial data readout anticipated in First Quarter 2026. Building on the progress of initiating UK-based clinical validation study, are also focusing on advancing U.S. regulatory and clinical development. To facilitate this, The company have begun discussions with renowned U.S. based clinical institutions to initiate studies to support IVD development. Additionally, activities have been initiated to submit a request for a formal meeting with the FDA through its pre-submission program, also known as Q-submission. This will allow the company to receive formal written feedback from the FDA regarding ViraxImmune™ IVD clinical development and regulatory plans in the U.S., including guidance on clinical validation and performance testing. The company anticipates receiving the FDA written feedback by Second Quarter of 2025, followed by the initiation of U.S. based clinical validation study. In addition, as part of launch and commercialization plans for ViraxImmune™ IVD platform, aim to establish strategic collaborations with CLIA laboratories in the U.S. to offer laboratory development tests (LDTs) for clinical studies to support the development of ViraxImmune™ platform. The company have initiated consulting activities in the U.S. with external partners to assist with market research and pricing activities needed for product placement of this launch. Alongside advancing the ViraxImmune™ IVD platform, The company launched research-use-only (RUO) ImmuneSelect portfolio in Second Quarter of 2024. ImmuneSelect is a commercially available suite of research-use-only (RUO) immune profiling solutions, including peptide pools, ELISpot kits, and recombinant antibodies. This enables researchers and drug developers to study T-cell activation, immune profiling, and immune. Reported Earnings • Nov 26
First half 2025 earnings released: US$0.89 loss per share (vs US$1.64 loss in 1H 2024) First half 2025 results: US$0.89 loss per share (improved from US$1.64 loss in 1H 2024). Net loss: US$2.76m (loss narrowed 5.3% from 1H 2024). Ankündigung • Nov 01
Virax Biolabs Group Limited, Annual General Meeting, Dec 12, 2024 Virax Biolabs Group Limited, Annual General Meeting, Dec 12, 2024. Location: biocity glasgow, boness road, newhouse, lanarkshire, ml1 5uh, United Kingdom Board Change • Nov 01
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Member of Advisory Board Nikolas Perrault is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Aug 23
Virax Biolabs Group Limited has filed a Follow-on Equity Offering in the amount of $4.990014 million. Virax Biolabs Group Limited has filed a Follow-on Equity Offering in the amount of $4.990014 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,108,892
Price\Range: $4.5
Discount Per Security: $0.315
Transaction Features: Registered Direct Offering Ankündigung • Aug 02
Virax Biolabs Group Limited announced delayed 20-F filing On 08/01/2024, Virax Biolabs Group Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. New Risk • Jul 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 72% per year over the past 5 years. Revenue is less than US$1m (US$79k revenue). Market cap is less than US$10m (US$3.00m market cap). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Shareholders have been diluted in the past year (32% increase in shares outstanding). Ankündigung • Jun 13
Virax Biolabs Group Limited Announces Executive Changes On June 11, 2024, Mr. Mark Ternouth resigned as Chief Technical Officer (“CTO”) of Virax Biolabs Group Limited (the “Company” or “Virax”)) and a director of the Board (the “Board”) of the Company, for personal reasons, effective immediately. On the same date, the Board appointed Dr. Nigel McCracken, Chief Operating Officer (“COO”), to fill in the vacancy on the Board, resulting from Mr. Mark Ternouth’s resignation, effective June 11, 2024. Since September 2023, Dr. Nigel McCracken has been serving as COO of Virax Biolabs Group Limited, responsible for running operations and development of the Company. Prior to joining the Company, from March 2021 to August 2023, Dr. McCracken served as the Chief Scientific Officer of BerGenBio AsA, a biopharmaceutical company. From May 2019 to March 2021, Dr. McCracken served as the Chief Operating Officer of NuCana PLC. From September 2014 to April 2019, Dr. McCracken served as the vice president of translational medicine and an executive board member of Debiopharm International SA, a biopharmaceutical company. Dr. McCracken obtained a Master’s degree in Clinical Pharmacology, a Doctor of Philosophy degree in Biochemical Toxicology from Newcastle University, and a Bachelor of Science degree in Biochemistry and Pharmacology from the University of Strathclyde, in 2015, 1991 and 1988, respectively. Ankündigung • Apr 26
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 Virax Biolabs Group Limited announced the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmune T-Cell diagnostic platform for research-use-only ("RUO"), at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress, which is taking place from April 27th to April 30th, 2024, in Barcelona, Spain. The Company is hosting at Booth F43, and management will be available for discussions with research organizations and potential partners. ImmuneSelect is the Company's new portfolio of immune profiling solutions dedicated to investigating adaptive immunity. ImmuneSelect is developed to evaluate T-Cell driven immunity and to aid in the understanding and early characterization of symptoms associated with post-viral syndromes, including Long COVID. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens linked to post-viral syndromed. These include pools for SARS-CoV-2, SARS-CoV- 2 MHC-1 ("CD8"), Lyme Disease, Cytomegalovirus ("CMV"), Respiratory Syncytial Virus ("RSV") and Epstein-Barr Virus ("EBV"). The exact underlying reason why people suffer from post-viral syndromES is not fully understood, however several factors are believed to play a role. These factors include problems with the immune system, such as ongoing chronic inflammation, autoimmunity, improper functioning of T-Cells and sometimes the reactivation of viruses that were previously dormant in the body. Currently, there are no reliable diagnostics for the early detection of post-viral syndrome, including Long COVID. New Risk • Jan 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 72% per year over the past 5 years. Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (US$79k revenue). Revenue is less than US$1m (US$79k revenue). Market cap is less than US$10m (US$2.53m market cap). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Share price has been volatile over the past 3 months (15% average weekly change). Ankündigung • Jan 23
Virax Biolabs Group Limited has filed a Follow-on Equity Offering in the amount of $1.455029 million. Virax Biolabs Group Limited has filed a Follow-on Equity Offering in the amount of $1.455029 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Reported Earnings • Jan 14
First half 2024 earnings released: US$1.64 loss per share (vs US$1.24 loss in 1H 2023) First half 2024 results: US$1.64 loss per share (further deteriorated from US$1.24 loss in 1H 2023). Net loss: US$2.91m (loss widened 102% from 1H 2023). Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Healthcare industry in the US. New Risk • Jan 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (over 13x increase in shares outstanding). Revenue is less than US$1m (US$8.6k revenue). Revenue is less than US$1m (US$8.6k revenue). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (15% average weekly change). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$26.4m market cap). New Risk • Dec 29
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 13x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (over 13x increase in shares outstanding). Revenue is less than US$1m (US$8.6k revenue). Revenue is less than US$1m (US$8.6k revenue). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (US$29.2m market cap). New Risk • Oct 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (US$8.6k revenue). Market cap is less than US$10m (US$4.74m market cap). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change). Ankündigung • Oct 19
Virax Biolabs Group Limited announced that it has received $2.15 million in funding On October 17, 2023, Virax Biolabs Group Limited closed the transaction. The transaction included participation from a single investor. Ankündigung • Sep 02
Virax Biolabs Group Limited Announces Management Changes Virax Biolabs Group Limited announced the appointment of Dr. Nigel McCracken as the Company's Chief Operating Officer ("COO"). Dr. McCracken will succeed Mr. Cameron Shaw, who is moving to Virax's Advisory Board, and will lead the Company's various growth initiatives, including the Company's expected near-term research-use-only launch of ViraxImmune™. On September 1, 2023, Mr. Cameron Shaw resigned as a director of the board. As COO, Dr. McCracken will lead Virax's research and clinical teams as well as the execution of the Company's go-to-market strategy for ViraxImmune™. Prior to joining Virax, Dr. McCracken was the Chief Scientific Officer at OTC traded BerGenBio AsA where he drove the plan for BerGenBio AsA's companion diagnostics and assay development. Prior to that role, he served as COO at Nasdaq listed NuCana PLC, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, where he provided oversight and direction to the operations of the business, research and development, and execution of corporate strategy. Dr. McCracken obtained a Master’s degree in Clinical Pharmacology, a Doctor of Philosophy degree in Biochemical Toxicology from Newcastle University, and a Bachelor of Science degree in Biochemistry and Pharmacology from the University of Strathclyde, in 2015, 1991 and 1988, respectively. In addition, Mark Ternouth, Virax's current Chief Technology Officer, will be joining the company's Board of Directors. Mr. Ternouth brings decades of experience with companies such as KPMG, PricewaterhouseCoopers (PwC), COLT Telecom, John Lewis Partnership and the United Kingdom's Home Office and Ministry of Justice. Ankündigung • Aug 04
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid Virax Biolabs Group Limited ("Virax" or the "Company") announced that Nasdaq has approved the Company's request for a 180-day extension to meet the $1 minimum bid price requirement. On January 30, 2023, Nasdaq provided notice to the Company that based on the previous 30 consecutive business days, the Company's listed common stock no longer met the minimum $1 bid price per share requirement as set in Nasdaq Listing Rule 5810(c)(3)(A)(ii). The Company was provided 180 calendar days, or until July 31, 2023, to regain compliance. Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until January 29, 2024, to regain compliance. If at any time during this additional time period the closing bid price of the Company's security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance. Ankündigung • Jan 05
Virax Biolabs Introduces Human Papillomavirus Test Kit Virax Biolabs announced the distribution of HPV test kits with shipments anticipated in First Quarter of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contacting the Company's sales representatives. HPV is one of the most prevalent sexually transmitted infections in the developed world. HPV is also the primary cause of cervical cancer in women with around 33,000 cases and 15,000 deaths annually in the EU, according to the European Centre for Disease Prevention and Control. Globally, HPV is estimated to cause over 600,000 cases of cervical cancer annually by the World Health Organization. Ankündigung • Dec 07
Virax Biolabs Group Limited Receives Emergency Use Authorization in the United States Virax Biolabs Group Limited announced that their supplier has received an Emergency Use Authorization from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test. The Tests are ready for sale in the US by Virax. Additionally, another Point of Care Rapid Antigen test to be distributed by Virax is seeking an approval with Health Canada for Canadian distribution. The Tests have been eligible for sale in markets accepting the CE Mark since 2020. COVID-19 remains a significant healthcare burden in the United States. According to the CDC, as of November 23, 2022, there have been approximately 45 million cases with around 250,000 deaths attributable to COVID-19 so far in 2022. Total test volume has been over 266 million in the US in 2022. The Test is intended for non-prescription self-use and for an adult lay user to test another person 2 years of age orolder in a non-laboratory setting via a nasal swab. The Test seeks to identify infections related to COVID-19 with results typically available in 10 minutes. Testing in symptomatic subjects indicate 98.8% sensitivity and 97.2%specificity. Ankündigung • Nov 19
Virax Biolabs Group Limited Announces Board Changes The board of directors of Virax Biolabs Group Limited announced that effective November 17, 2022, Mr. Nelson Haight was appointed as an independent director of the company. On the same day, Ms. Margaret E. Gilmour resigned as an independent director of the board due to personal reasons. Ms. Gilmour’s resignation was not a result of any disagreement with the board of the company or the company. The biographies for Mr. Haight is set forth below: Nelson Haight, age 57, has been as its independent director since November 17, 2022. A finance executive with over 30 years of professional experience, Mr. Nelson Haight currently serves as Executive Vice President and Chief Financial Officer of TEAM Inc., which he joined in June 2022. Previously from June 2020 to June 2022, he served as Senior Vice President, Chief Financial Officer and Treasurer for Key Energy Services Inc. From September 2019 to June 2020, Mr. Haight was the interim Chief Financial Officer for Element Markets, LLC, an environmental commodities firm. From November 2018 to June 2019, Mr. Haight was the interim Chief Financial Officer for Epic Companies, LLC, a family office backed oilfield service company. Between July 2017 and September 2018, Mr. Haight was the Chief Financial Officer of Castleton Resources, LLC, a privately held exploration and production company. From December 2011 to July 2017, Mr. Haight served in various capacities from Vice President to Chief Financial Officer at Midstates Petroleum Company Inc. Mr. Haight served as a member of the board of directors of Mountain Crest Acquisition Corp. from January 2020 to February 2021 and served as a member of the board of directors of Mountain Crest Acquisition Corp. II from October 2020 to October 2021. He has been serving as a member of the board of directors of Mountain Crest Acquisition Corp. III since March 2021. He has also been serving as a member of the board of directors of Mountain Crest Acquisition Corp. IV since March 2021. He has also been serving as a member of the board of directors of Mountain Crest Acquisition Corp. V since April 2021. Mr. Haight received an MPA and BBA from the University of Texas at Austin in May 1988 and is a Certified Public Accountant and member of the American Institute of Certified Public Accountants. Board Change • Nov 16
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Member of Advisory Board Nikolas Perrault is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Nov 04
Virax Biolabs Introduces RSV-Influenza-Covid Triple Virus Antigen Rapid Test Kit Virax Biolabs announced the distribution of a RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in both at-home and in point-of-care settings to accurately identify infections related to respiratory syncytial virus (RSV), influenza and COVID-19 with results typically available in 15 minutes. The specialized diagnostic kits can be found by contacting the company's sales representatives. While lesser known to the general public than influenza and COVID-19, RSV can be a serious illness. According to the European Health Management Association, RSV is the most common cause of hospitalization in infants and also causes a large number of hospitalizations among the elderly. RSV infection can lead to pneumonia, congestive heart failure and severe symptoms in those with preexisting conditions involving the lungs. The RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit is an in vitro immunochromatographic assay for the qualitative and differential detection of nucleocapsid protein antigen from influenza A (including the subtype H1N1), influenza B, RSV and COVID-19 in nasal swab specimens from individuals with or without symptoms or other epidemiological reasons to suspect Flu A/B, RSV and /or COVID-19 infections. Board Change • Oct 29
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Member of Advisory Board Nikolas Perrault is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Oct 27
Virax Biolabs Group Limited Announces Initiation of Its Virax Immune COVID-19 Analytical Performance Study Virax Biolabs Group Limited announced the initiation of its Virax Immune COVID-19 Analytical Performance Study scheduled to take place through Fourth Quarter of this year and finishing in First Quarter of next year. The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit and will include specimens from 96 healthy volunteers. Virax Immune is a proprietary T-Cell In-Vitro Diagnostic ("IVD") test technology being developed with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. Unlike antibodies, T-Cells coordinate the immune system against major global viral attacks and have been shown to provide a level of protection against Covid-19 and its variants that is more robust and long-lasting than an antibody mediated response. Their detection can give an indication of inherent protection from disease for those yet to be infected and may be useful to determine the degree of long-term protection an individual has after recovering from major global viral threats. The first test being developed using the Virax Immune platform is for immunity related to COVID-19. Using data from the IVD test, proprietary mobile application would be set up to offer an algorithmic immunological profile for patients, which would provide information such as if vaccination has been successful in providing protection or if additional vaccination boosters are required. Additional tests may be developed in the future for new global pandemics and for such viruses as Human Papillomavirus (better known as HPV), Malaria, Hepatitis B, and Herpes (better known as HSV-1). T-Cell tests have been designed to be as affordable and scalable as possible, by avoiding the requirement for complex processes and expensive lab equipment. The 'lab agnostic' nature of the tests is intended to result in penetration of both established and emerging markets in the near term across a variety of pathogens. Ankündigung • Sep 21
Virax Biolabs Group Limited Introduces Monkeypox Virus Antigen Rapid Test Kit Virax Biolabs Group Limited announced the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes. It also serves as a valuable initial screening test for individuals that have been exposed to monkeypox infected patients or a high-risk environment. The specialized diagnostic kits can be found by contacting the company's sales representatives. The Monkeypox Virus Antigen Rapid Test Kits are used for in vitro qualitative detection of the monkeypox virus antigen in the oropharyngeal (throat) swabs and skin exudates of humans by colloidal gold immunochromatography. Ankündigung • Jul 30
Virax Biolabs Group Limited announced delayed 20-F filing On 07/29/2022, Virax Biolabs Group Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC. Ankündigung • Jul 27
Virax Biolabs Group Limited Launches Distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits Virax Biolabs Group Limited launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the major Monkeypox outbreak. These specialized diagnostic kits are available now in Europe and can be found by contacting the company’s sales representatives. The test is intended to aid in the rapid diagnosis of Monkeypox and varicella-zoster viruses in human serum and lesion exudate specimens, providing a preliminary test result. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Reported Earnings • Jul 24
First half 2022 earnings released: US$0.059 loss per share (vs US$0.10 loss in 1H 2021) First half 2022 results: US$0.059 loss per share. Revenue: US$0 (down 100% from 1H 2021). Net loss: US$552.4k (loss widened 80% from 1H 2021). Profit margin: (up from net loss in 1H 2021). The move to profitability was primarily driven by lower revenue. Ankündigung • Jul 22
Virax Biolabs Group Limited has completed an IPO in the amount of $6.75 million. Virax Biolabs Group Limited has completed an IPO in the amount of $6.75 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,350,000
Price\Range: $5
Discount Per Security: $0.35 Board Change • Jul 13
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Member of Advisory Board Nikolas Perrault is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 
